Akero Therapeutics, Inc.
AKRODrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Efruxifermin | Phase 3 | NASH - Nonalcoholic Steatohepatitis | - | - |
EFX | Phase 2 | NASH - Nonalcoholic Steatohepatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Akero Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Akero Therapeutics, Inc.'s (AKRO) pipeline across Phase 3, Phase 2. Its lead program is Efruxifermin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Akero Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Akero Therapeutics, Inc. (AKRO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AKRO biotech catalysts?→
Add AKRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Akero Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.